Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Novel Anticancer Drug Restores Tumor Cell Apoptotic Pathways

By BiotechDaily International staff writers
Posted on 29 Apr 2013
Image: Dr. Guillaume Lessene (above) and his collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients (Photo courtesy of Walter and Eliza Hall Institute, Australia).
Image: Dr. Guillaume Lessene (above) and his collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients (Photo courtesy of Walter and Eliza Hall Institute, Australia).
Cancer researchers have developed a drug that blocks a prosurvival gene in cancer cells and renders them vulnerable to elimination from the body by classical cell death (apoptotic) pathways.

The prosurvival protein BCL-XL is often overexpressed in solid tumors and it renders malignant tumor cells resistant to anticancer therapeutics. BCL-XL (B-cell lymphoma-extra-large) is a transmembrane molecule in the mitochondria. It is a member of the BCL-2 family of proteins, and acts as a prosurvival protein by preventing the release of mitochondrial contents such as cytochrome c, which would lead to caspase activation. BCL-2 (B-cell lymphoma 2) was the founding member of the BCL-2 family of apoptosis regulator proteins encoded by the gene of the same name. The formal name for BCL-2 is B-cell lymphoma 2, as it was the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas.

Investigators at the Walter and Eliza Hall Institute (Victoria, Australia) and their colleagues at the biotech company Genentech (San Francisco, CA, USA) sought to develop a drug that would inhibit specifically BCL-XL without affecting other BCL-2 family proteins.

To this end, they employed a high-throughput screen to discover a new series of small molecules targeting BCL-XL and then used this structure to guide development of the drug by medicinal chemistry. They reported in the April 21, 2013, online edition of the journal Nature Chemical Biology that the optimized compound, WEHI-539, had high affinity (subnanomolar range) and selectivity for BCL-XL and potently killed cells by selectively antagonizing its prosurvival activity. WEHI-539 was found to belong to the class of anti-cancer drugs called "BH3-mimetics.” Other drugs in this class include navitoclax (ABT-263) and ABT-199/GDC-0199, which are currently in clinical trials for the treatment leukemia and lymphoma.

Senior author Dr. Guillaume Lessene, professor of chemical biology at the Walter and Eliza Hall Institute, said, "That the development of WEHI-539 was an important milestone on the way to creating potential anticancer agents that act to restore cell death by inhibiting BCL-XL. Although WEHI-539 is not optimized for use in patients, it will be a very valuable tool for researchers to use to dissect how BCL-XL controls cancer cell survival."

"We were very excited to see the team's work culminate in a compound that specifically inhibits BCL-XL," said Dr. Lessene. "WEHI-539 is the first compound that our chemists have developed from scratch, using the three-dimensional structure of BCL-XL to build and refine its design."

Related Links:

Walter and Eliza Hall Institute
Genentech



BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.